Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse outcomes.
We did a national, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE) across primary care centres in the UK. We included people aged 65 years or older, or 50 years or older with comorbidities (weakened immune system, heart disease, hypertension, asthma or lung disease,
– Evidence-of-concept analyze of VX-548 in acute ache adhering to bunionectomy surgical procedure open for enrollment –
– Second Period 2 analyze of VX-548 in acute soreness next abdominoplasty operation to get started in the coming weeks –
BOSTON, July 19, 2021–(Enterprise WIRE)–Vertex Prescription drugs Integrated (Nasdaq: VRTX) these days announced that it has begun a Phase 2 evidence-of-strategy (POC) research in acute agony adhering to bunionectomy surgical treatment with the selective NaV1.8 inhibitor VX-548 and that it expects to start a next Period 2 study in acute discomfort subsequent abdominoplasty surgical treatment in the coming
Ivermectin, a drug used to treat parasite infections in livestock and humans, is set to be investigated as a possible treatment for COVID-19 in a large United Kingdom study which is being conducted at the University of Oxford.
Lab studies have shown that the use of the therapy reduces the replication of SARS-CoV-2, with other smaller pilot studies demonstrating a reduction in viral load and duration of symptoms with early administration.
The therapy will be added to the PRINCIPAL Trial, a large clinical trial designed to assess potential COVID-19 therapies for non-hospitalized patients, including at-home recovery, who are at higher